Complete population (N=370) n (%) | Maintenance population (N=227) n (%) | |
---|---|---|
Race | 370 (100.0) | 227 (100.0) |
Caucasian | 147 (39.7) | 99 (43.6) |
Black | 46 (12.4) | 23 (10.1) |
Asian | 123 (33.2) | 76 (33.5) |
Other | 54 (14.6) | 29 (12.8) |
Ethnicity | 370 (100.0) | 227 (100.0) |
Hispanic | 131 (35.4) | 77 (33.9) |
Non-Hispanic | 239 (64.6) | 150 (66.1) |
Age at randomisation (years) | 370 (100.0) | 227 (100.0) |
≤20 | 50 (13.5) | 35 (15.4) |
>20 and ≤30 | 124 (33.5) | 73 (32.2) |
>30 and ≤40 | 120 (32.4) | 77 (33.9) |
>40 | 76 (20.5) | 42 (18.5) |
Biopsy class | 370 (100.0) | 227 (100.0) |
III/IV | 260 (70.3) | 169 (74.4) |
III/V or IV/V | 50 (13.5) | 23 (10.1) |
V | 60 (16.2) | 35 (15.4) |
Lupus nephritis duration (years) | 370 (100.0) | 227 (100.0) |
≤1 | 236 (63.8) | 155 (68.3) |
>1 and <5 | 69 (18.7) | 31 (13.7) |
≥5 | 65 (17.6) | 41 (18.1) |
eGFR baseline (mL/min/1.73 m2) | 332 (100.0) | 227 (100.0) |
<90 | 188 (56.6) | 131 (57.7) |
≥90 | 144 (43.4) | 96 (42.3) |
Anti-dsDNA baseline (IU/mL) | 325 (100.0) | 222 (100.0) |
Negative (<30) | 14 (4.3) | 14 (6.3) |
Positive (≥30) | 311 (95.7) | 208 (93.7) |
C3 baseline (mg/dL) | 328 (100.0) | 224 (100.0) |
≥90 | 80 (24.4) | 50 (22.3) |
<90 | 248 (75.6) | 174 (77.7) |
C4 baseline (mg/dL) | 327 (100.0) | 223 (100.0) |
≥16 | 111 (33.9) | 70 (31.4) |
<16 | 216 (66.1) | 153 (68.6) |
UP/C baseline | 325 (100.0) | 223 (100.0) |
≤1 | 53 (16.3) | 33 (14.8) |
>1 and ≤3 | 123 (37.8) | 88 (39.5) |
>3 | 149 (45.9) | 102 (45.7) |
Antimalarial treatment | 370 (100.0) | 227 (100.0) |
Concomitant treatment with anti-malarials | 127 (34.3) | 84 (37.0) |
No antimalarial treatment | 243 (65.7) | 143 (63.0) |
Lipid-modifying agent treatment | 370 (100.0) | 227 (100.0) |
Statin | 85 (23.0) | 52 (22.9) |
No statin | 285 (77.0) | 175 (77.1) |
Induction treatment | 370 (100.0) | 227 (100.0) |
MMF | 185 (50.0) | 120 (52.9) |
IVC | 185 (50.0) | 107 (47.1) |
Anti-dsDNA, anti-double-stranded DNA; eGFR, estimated glomerular filtration rate; ITT, intention to treat; IVC, intravenous cyclophosphamide; MMF, mycophenolate mofetil; UP/C, urine protein:creatinine ratio.